AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 DEC 5 - (NewsRx.com & NewsRx.net) -- Ostex International, Inc., (OSTX) reported results of operations for the 3 and 9-month periods ended September 30, 2002.
Total revenue for the third quarter was $1,655,000, as compared with third quarter 2001 revenue of $1,286,000. The increase in revenue for the 3 months ended September 30, 2002, was primarily due to greater shipments of Osteomark NTx Urine and Serum tests, offset by lower sales of the company's NTx Point-of-Care Device. Sales were particularly strong from the company's Japanese partner, Mochida Pharmaceutical Co., Ltd. For the 9-month period ended September 30, 2002, total revenue was $4,150,000 versus $4,307,000 for the same period in the prior year.
The company recorded a third quarter 2002 net loss of $1,125,000 ($0.09 per share) compared with a loss of $737,000 ($0.06 per share) for the corresponding quarter of the prior year. Contributing ...